Cepheid Breaks Losing Streak, Gains 4% (CPHD)

Today, molecular diagnostics company Cepheid (NASDAQ: CPHD), which was on a decline after reporting a fiscal 2012 third-quarter loss and a lowered annual revenue and income guidance, went to the brink of hitting a new 52-week low price. After two successive days of declines last week, the share price opened at $30.31, a few notches above the 52-week low of $29.90 per share, and recovered from the negative territory to pose a 4.2% gain at the end of the day.

The California-based company is involved in the development and manufacture of easy-to-use molecular systems and tests. Cepheid is focused on automating highly complex and time-consuming manual procedures such as genetic testing for organisms and developing applications for managing infectious diseases and cancer.

On October 18, Cepheid reported an increase in the fiscal 2012 third-quarter revenue to $80.5 million from $70.2 million in the prior-year corresponding period. The net loss for the third-quarter was $21.3 million, or $0.32 per share, compared to a net profit of $1.92 million, or $0.03 per share, in the third-quarter of fiscal 2011. The company had paid a litigation settlement charge of $15.1 million during the third-quarter.

Excluding the litigation settlement, employee stock-based compensation and amortization of purchased intangible assets, non-GAAP net income for the third-quarter decreased to $0.9 million from non-GAAP net income of $7.6 million in the year-ago corresponding quarter. According to FactSet, analysts expected the company to report $80.7 million in revenue and income of $0.01 per share for the reported quarter.

From a low of $34.53 per share in the last week of January 2012, Cepheid rose to $44.91 per share on February 6, owing to the fiscal 2011 fourth-quarter results that beat analysts’ estimates and a fiscal 2012 full-year guidance that was way better than what the analysts had expected. However, a cut in fiscal 2012 full-year guidance issued on July 19 brought the share price back to $32.13 per share on July 24. On August 6, Cepheid announced a series of agreements with the Bill & Melinda Gates Foundation, the United States President’s Emergency Plan for AIDS Relief (PEPFAR), the United States Agency for International Development (USAID) and UNITAID to buy-down the price of the Xpert MTB/RIF test for High Burden Developing Countries (HBDCs). The news propelled the share price back to $40.12 per share on September 7.

On September 26, Cepheid issued a fiscal 2012 third-quarter revenue warning that led the fall in the share price to $34.48 on October 1. Following the report of a third-quarter loss, the share price plunged to $30.59.

For the fiscal year 2012 ending December 2012, the company now expects to report total revenue of approximately $333 million, which is at the lower end of the previously issued revenue guidance range of $333 million to $347 million. Cepheid also lowered its full-year income guidance from break even to $0.04 per share to a net loss in the range of $0.42 to $0.40 per share. The company anticipates a non-GAAP net income in the range of $0.21 to $0.23 per share. On an average, analysts are expecting a net income of $0.01 per share and revenue of $332.9 million.

Cepheid ended the day at $31.87 per share, up $1.28 or 4.2% on a volume of 942,592 shares.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Duncan Oleinic

Duncan Oleinic is from New Yourk. After graduating with a degree in physics, he began his career as an analyst in a broking firm. Through this experience he was able to advance to the role of correspondent for a U.S based financial news provider, where he worked from 2001 to 2007. He subsequently joined a merchant banking firm as a financial analyst focused on valuing unlisted companies in the sub-continent. Over the course of his two years here, he performed valuations of several media companies which were later acquired by peers.

Recent Stories

SignUp Now For Our Featured Newsletter